We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




World’s First Biomarker Blood Test to Assess MS Progression

By LabMedica International staff writers
Posted on 31 Dec 2025

Multiple sclerosis (MS) disease activity is caused by an abnormal immune response that results in damage to the brain and spinal cord. More...

However, there is a lack of reliable tools to measure or predict MS progression. Today, physicians and patients must rely on subjective assessments and infrequent imaging, leaving critical changes undetected until disability has advanced. Now, a new test combining multi-protein biomarkers with AI-driven algorithms aims to deliver objective scores that track progression over time, empowering physicians to make earlier, more confident treatment decisions.

Octave Bioscience (Menlo Park, CA, USA) is advancing the development of the Multiple Sclerosis Disease Progression (MSDP) Test, the world’s first biomarker blood test for MS progression. This test builds on the success of Octave’s MS Disease Activity (MSDA) Test, the first validated AI-enabled multi-protein blood test for MS. Octave’s test will combine multi-protein biomarkers with AI-driven algorithms to deliver objective scores that track progression over time, empowering physicians to make earlier, more confident treatment decisions.

Delivered as a simple blood test, the MSDP Test is being designed for all MS patients, including Relapsing Remitting MS (RRMS), Primary Progressive MS (PPMS), and Secondary Progressive MS (SPMS). Octave will make efforts to identify individual proteins and develop multi-analyte biomarker models, advancing the MSDP Test toward commercial viability as a complementary solution to MSDA.

In collaboration with leading academic partners worldwide, Octave will use advanced assays to study proteins in MS patients, with findings to be published in a leading peer-reviewed journal. The MSDP Test addresses one of the most urgent unmet needs in MS: the lack of reliable tools to measure or predict progression.

“Octave is poised to tackle one of the most critical problems facing the MS field, that of reliably measuring the biology of progressive disease,” said Dr. Jennifer Graves, Senior Medical Advisor at Octave. “If you can measure something, you can target it. Octave's delivery of a progressive MS biomarker test will fuel therapeutic development and improved management of the most challenging aspects of MS.”

Related Link
Octave Bioscience


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.